These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 31750249)

  • 1. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis.
    Wu Y; Xu J; Du C; Wu Y; Xia D; Lv W; Hu J
    Front Oncol; 2019; 9():1161. PubMed ID: 31750249
    [No Abstract]   [Full Text] [Related]  

  • 2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Predictive Value of Tumor Mutation Burden on Clinical Efficacy of Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Meta-Analysis.
    Ning B; Liu Y; Wang M; Li Y; Xu T; Wei Y
    Front Pharmacol; 2022; 13():748674. PubMed ID: 35355708
    [No Abstract]   [Full Text] [Related]  

  • 4. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
    Front Oncol; 2022; 12():795933. PubMed ID: 35223476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
    Front Immunol; 2021; 12():751407. PubMed ID: 34659255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
    Qian X; Chen H; Tao Y
    Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis.
    Xiang X; Li Y; Yang X; Guo W; Zhou P
    BMJ Open; 2022 Aug; 12(8):e058692. PubMed ID: 35926995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer.
    Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM
    J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The predictive value of tumor mutation burden on survival of gastric cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis.
    Ke L; Li S; Huang D
    Int Immunopharmacol; 2023 Nov; 124(Pt B):110986. PubMed ID: 37748223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prognostic role of tumor mutation burden on survival of breast cancer: a systematic review and meta-analysis.
    Ke L; Li S; Cui H
    BMC Cancer; 2022 Nov; 22(1):1185. PubMed ID: 36397030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Kim JY; Kronbichler A; Eisenhut M; Hong SH; van der Vliet HJ; Kang J; Shin JI; Gamerith G
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31731749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
    Shim JH; Kim HS; Cha H; Kim S; Kim TM; Anagnostou V; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
    Ann Oncol; 2020 Jul; 31(7):902-911. PubMed ID: 32320754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC).
    Ma X; Zhang Y; Wang S; Yu J
    J Cancer; 2021; 12(2):584-594. PubMed ID: 33391454
    [No Abstract]   [Full Text] [Related]  

  • 15. The predictive efficacy of tumor mutation burden in immunotherapy across multiple cancer types: A meta-analysis and bioinformatics analysis.
    Cao J; Yang X; Chen S; Wang J; Fan X; Fu S; Yang L
    Transl Oncol; 2022 Jun; 20():101375. PubMed ID: 35339028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: a meta-analysis.
    Wan L; Wang Z; Xue J; Yang H; Zhu Y
    Transl Cancer Res; 2020 Sep; 9(9):5437-5449. PubMed ID: 35117909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Nan Z; Guoqing W; Xiaoxu Y; Yin M; Xin H; Xue L; Rong W
    Biomed Res Int; 2021; 2021():1780860. PubMed ID: 33791360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers and factors in small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Li LL; Yu CF; Xie HT; Chen Z; Jia BH; Xie FY; Cai YF; Xue P; Zhu SJ
    Cancer Med; 2023 May; 12(10):11211-11233. PubMed ID: 37161541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis.
    Zhao J; Dong Y; Bai H; Duan J; Wang G; Xu J; Wang J; Wang Z
    J Natl Cancer Cent; 2022 Mar; 2(1):41-49. PubMed ID: 39035215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Huang T; Chen X; Zhang H; Liang Y; Li L; Wei H; Sun W; Wang Y
    Front Oncol; 2021; 11():706652. PubMed ID: 34395281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.